Zinc Finger Nucleases Targeting HSV-2 for Vaccine Development
Author Information
Author(s): Wayengera Misaki
Primary Institution: Makerere University
Hypothesis
Can zinc finger nucleases (ZFNs) be engineered to specifically target and disrupt herpes simplex virus type II (HSV-2) genomic DNA?
Conclusion
ZFNs with specificity to HSV-2 genomic DNA that are precursors of novel host-genome expressed HSV-2 gene-therapeutics or vaccines were identified.
Supporting Evidence
- Existing treatments for HSV-2 only address symptoms and do not eliminate the virus.
- Zinc finger nucleases can be engineered to specifically target HSV-2 DNA without affecting human DNA.
- Over 60% of HSV-2 genomic material can potentially be excised from infected cells using the identified ZFNs.
Takeaway
Scientists found a way to create special tools that can cut the DNA of the herpes virus, which could help make new vaccines or treatments.
Methodology
The study used computational software to identify over 28,000 zinc finger arrays (ZFAs) and constructed 684 zinc finger nucleases (ZFNs) specific to HSV-2 genomic DNA.
Potential Biases
Potential bias may arise from the author's affiliation with a biotherapeutics company.
Limitations
The study does not address the long-term effects of ZFN application on the host genome or the potential for off-target effects.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website